Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine

The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.

Study Overview

• Status: Completed
• Conditions: Hand, Foot and Mouth Disease
• Intervention / Treatment: Biological: EV71 Vaccine only; Biological: Concomitant administration of EV71 vaccine with EPI vaccines; Biological: Single injection of EPI vaccine

Detailed Description

This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine. 780 healthy infants of 6 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)& recombinant hepatitis B vaccine on day 0 and EV71 vaccine (second dose)& Group A meningococcal polysaccharide vaccine on day 30. The group II receive recombinant hepatitis B vaccine on day 0 and Group A meningococcal polysaccharide vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.

• Study Type: Interventional
• Enrollment (Actual): 780
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Dongguan, Guangdong, China, 523129
      • Dongguan Municipal Center for Disease Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 6 months (CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy volunteers aged 6 months
• Finished two doses of vaccination (0,1 month) of hepatitis B vaccine prior to study entry
• Proven legal identity
• Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study

Exclusion Criteria:

• Finished all the three doses vaccination (0,1,6 month) of hepatitis B vaccine prior to study entry
• Prior vaccination of meningococcal polysaccharide vaccine
• Prior vaccination of EV71 vaccine
• Unable to receive vaccination on both arms
• History of hand foot and mouth disease
• Previously tested HBsAg positive
• Mother of the subject had been previously tested HBsAg positive
• History of asthma; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc
• Congenital malformation, developmental disorders, genetic defects
• Autoimmune disease or immunodeficiency/immunosuppressive
• Severe nervous system disease or mental illness
• Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders
• Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry
• Receipt of blood product (e.g., immunoglobulin) within 3 months prior to study entry
• Receipt of any other investigational medicine(s) within 30 days prior to study entry
• Receipt of any live attenuated vaccine within 14 days prior to study entry
• Receipt of any subunit vaccine or inactivated vaccine within 7 days prior to study entry
• Acute disease or acute stage of chronic disease within 7 days prior to study entry
• Axillary temperature > 37.0 ℃
• Any other factor that suggesting the volunteer is unsuitable for this study based on the judgement of investigators

Exclusion Criteria of the Second Injection:

• Subjects with one of the following 1 to 3 conditions are forbidden to continue vaccination, while the other study steps could be carried out based on the judgement of investigator; for subjects with one of the following 4 to 5 conditions, whether to continue vaccination are determined by the investigator; for subjects with one of the following 6 to 7 conditions, vaccination may be delayed in the time window specified in the study:

  1. Any serious adverse event that has a causal relationship with the investigated vaccine (except the group II)
  2. Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination, except the group II )
  3. Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection)
  4. New chronic diseases or acute stage of chronic diseases
  5. Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions) determined by the investigators
  6. Acute diseases (moderate or severe diseases with or without fever)
  7. Axillary temperature> 37.0 ℃

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Group I-EV71 vaccine and EPI vaccines; Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.	Biological: Concomitant administration of EV71 vaccine with EPI vaccines; The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.; The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
ACTIVE_COMPARATOR: Group II-EPI vaccine only; Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.	Biological: Single injection of EPI vaccine; The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.; The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
ACTIVE_COMPARATOR: Group III-EV71 vaccine only; EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.	Biological: EV71 Vaccine only; The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The seropositive rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody 1 month after 2 doses of vaccination	Immunogenicity indicator	30 days after 2 doses of injection

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of solicited local or systemic adverse events within 7 days after each dose	Safety indicator	7 days after each dose of injection
Incidence of unsolicited local or systemic adverse events within 30 days after each dose	Safety indicator	30 days after each dose of injection
Incidence of serious adverse events during the period of safety monitoring	Safety indicator	60 days after the first dose injection
The seroconversion rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody(SBA) 1 month after 2 doses of vaccination	Immunogenicity indicator	30 days after 2 doses of injection
EV71 neutralizing antibody GMT, anti-HBs GMC and SBA antibody GMT 1 month after 2 doses of vaccination	Immunogenicity indicator	30 days after 2 doses of injection

Collaborators and Investigators

• Sponsor: Sinovac Biotech Co., Ltd
• Collaborators: Guangdong Center for Disease Prevention and Control
• Investigators: Principal Investigator: Huizhen Zheng, Guangdong Center for Disease Prevention and Control

Publications and helpful links

General Publications

• Zhang Z, Liang Z, Zeng J, Zhang J, He P, Su J, Zeng Y, Fan R, Zhao D, Ma W, Zeng G, Zhang Q, Zheng H. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial. J Infect Dis. 2019 Jul 2;220(3):392-399. doi: 10.1093/infdis/jiz129.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 22, 2017
• Primary Completion (ACTUAL): November 1, 2017
• Study Completion (ACTUAL): November 1, 2017

Study Registration Dates

• First Submitted: September 4, 2017
• First Submitted That Met QC Criteria: September 4, 2017
• First Posted (ACTUAL): September 6, 2017

Study Record Updates

• Last Update Posted (ACTUAL): July 29, 2021
• Last Update Submitted That Met QC Criteria: July 26, 2021
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Keywords: Safety; Immunogenicity; Infant; Inactivated Enterovirus Type 71 (EV71) Vaccine; Concomitant vaccination
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Stomatognathic Diseases; Enterovirus Infections; Picornaviridae Infections; Coxsackievirus Infections; Mouth Diseases; Foot-and-Mouth Disease; Hand, Foot and Mouth Disease; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: PRO-EV71-4003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No